Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox.
Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, Eisenberg RJ, Hartmann CJ, Jackson DL, Kulesh DA, Martinez MJ, Miller DM, Mucker EM, Shamblin JD, Zwiers SH, Huggins JW, Jahrling PB, Moss B. Earl PL, et al. Among authors: eller la. Nature. 2004 Mar 11;428(6979):182-5. doi: 10.1038/nature02331. Nature. 2004. PMID: 15014500
Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.
Earl PL, Americo JL, Wyatt LS, Eller LA, Montefiori DC, Byrum R, Piatak M, Lifson JD, Amara RR, Robinson HL, Huggins JW, Moss B. Earl PL, et al. Among authors: eller la. Virology. 2007 Sep 15;366(1):84-97. doi: 10.1016/j.virol.2007.02.041. Epub 2007 May 11. Virology. 2007. PMID: 17499326 Free PMC article.
Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines.
Earl PL, Cotter C, Moss B, VanCott T, Currier J, Eller LA, McCutchan F, Birx DL, Michael NL, Marovich MA, Robb M, Cox JH. Earl PL, et al. Among authors: eller la. Vaccine. 2009 Sep 25;27(42):5885-95. doi: 10.1016/j.vaccine.2009.07.039. Epub 2009 Aug 3. Vaccine. 2009. PMID: 19654066 Free PMC article.
Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.
Cox JH, Ferrari MG, Earl P, Lane JR, Jagodzinski LL, Polonis VR, Kuta EG, Boyer JD, Ratto-Kim S, Eller LA, Pham DT, Hart L, Montefiori D, Ferrari G, Parrish S, Weiner DB, Moss B, Kim JH, Birx D, VanCott TC. Cox JH, et al. Among authors: eller la. Vaccine. 2012 Feb 27;30(10):1830-40. doi: 10.1016/j.vaccine.2011.12.131. Epub 2012 Jan 9. Vaccine. 2012. PMID: 22234262 Free PMC article.
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys.
Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, Liu J, Abbink P, Maxfield LF, Seaman MS, Dugast AS, Alter G, Ferguson M, Li W, Earl PL, Moss B, Giorgi EE, Szinger JJ, Eller LA, Billings EA, Rao M, Tovanabutra S, Sanders-Buell E, Weijtens M, Pau MG, Schuitemaker H, Robb ML, Kim JH, Korber BT, Michael NL. Barouch DH, et al. Among authors: eller la. Cell. 2013 Oct 24;155(3):531-9. doi: 10.1016/j.cell.2013.09.061. Epub 2013 Oct 24. Cell. 2013. PMID: 24243013 Free PMC article.
B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies.
Townsley SM, Donofrio GC, Jian N, Leggat DJ, Dussupt V, Mendez-Rivera L, Eller LA, Cofer L, Choe M, Ehrenberg PK, Geretz A, Gift S, Grande R, Lee A, Peterson C, Piechowiak MB, Slike BM, Tran U, Joyce MG, Georgiev IS, Rolland M, Thomas R, Tovanabutra S, Doria-Rose NA, Polonis VR, Mascola JR, McDermott AB, Michael NL, Robb ML, Krebs SJ. Townsley SM, et al. Among authors: eller la. Cell Host Microbe. 2021 Apr 14;29(4):564-578.e9. doi: 10.1016/j.chom.2021.01.016. Epub 2021 Mar 3. Cell Host Microbe. 2021. PMID: 33662277 Free PMC article.
HIV Antibody Profiles in HIV Controllers and Persons With Treatment-Induced Viral Suppression.
Kammers K, Chen A, Monaco DR, Hudelson SE, Grant-McAuley W, Moore RD, Alter G, Deeks SG, Morrison CS, Eller LA, Blankson JN, Laeyendecker O, Ruczinski I, Eshleman SH, Larman HB. Kammers K, et al. Among authors: eller la. Front Immunol. 2021 Aug 26;12:740395. doi: 10.3389/fimmu.2021.740395. eCollection 2021. Front Immunol. 2021. PMID: 34512672 Free PMC article.
Long-term antiretroviral therapy initiated in acute HIV infection prevents residual dysfunction of HIV-specific CD8+ T cells.
Takata H, Kakazu JC, Mitchell JL, Kroon E, Colby DJ, Sacdalan C, Bai H, Ehrenberg PK, Geretz A, Buranapraditkun S, Pinyakorn S, Intasan J, Tipsuk S, Suttichom D, Prueksakaew P, Chalermchai T, Chomchey N, Phanuphak N, de Souza M, Michael NL, Robb ML, Haddad EK, Crowell TA, Vasan S, Valcour VG, Douek DC, Thomas R, Rolland M, Chomont N, Ananworanich J, Trautmann L; RV254/SEARCH010, RV304/ SEARCH013, and SEARCH011 study groups. Takata H, et al. EBioMedicine. 2022 Oct;84:104253. doi: 10.1016/j.ebiom.2022.104253. Epub 2022 Sep 8. EBioMedicine. 2022. PMID: 36088683 Free PMC article.
109 results